Jeffrey Lahrmann, MD
Neurology · Vernon, CTNPI 1851770861
Payments from drug & device makers
Across 173 payments — averaging $89.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- AbbVie$439
- MDD US Operations, LLC$433
- Amneal Pharmaceuticals LLC$328
- Teva Pharmaceuticals USA, Inc.$273
- Kyowa Kirin, Inc.$255
- plus $1K from 17 others
What the payments were for
- Consulting fees$5083%
- Grants$7,50051%
- Travel & lodging$2,19415%
- Food & beverage$4,26829%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 46 | $12,377 |
| AbbVie(2 entities) | 26 | $439 |
| MDD US Operations, LLC | 18 | $433 |
| Amneal Pharmaceuticals LLC | 20 | $328 |
| Teva Pharmaceuticals USA, Inc. | 9 | $273 |
| Kyowa Kirin, Inc. | 8 | $255 |
| Acadia Pharmaceuticals Inc | 5 | $222 |
| Merz Pharmaceuticals, LLC | 6 | $160 |
| Neurocrine Biosciences, Inc. | 7 | $157 |
| Acorda Therapeutics, Inc | 3 | $146 |
| Boston Scientific | 1 | $108 |
| Noctrix Health, Inc. | 1 | $82 |
| Supernus Pharmaceuticals, Inc. | 6 | $70 |
| Lundbeck LLC | 1 | $65 |
| Sunovion Pharmaceuticals Inc. | 4 | $65 |
| Arbor Pharmaceuticals, Inc. | 3 | $61 |
| Adamas Pharmaceuticals, Inc. | 3 | $57 |
| Revance Therapeutics, Inc. | 1 | $49 |
| Abbott | 1 | $24 |
| Lilly USA, LLC | 1 | $22 |
| Avion Pharmaceuticals | 1 | $18 |
| GE HealthCare | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,439 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 87 | $810,158 |
| AustedoDeutetrabenazine | 54 | $283,109 |
| Austedo XrDeutetrabenazine | 25 | $206,582 |
| NuplazidPimavanserin Tartrate | 32 | $178,538 |
| RytaryCarbidopa/Levodopa | 86 | $136,016 |
| OngentysOpicapone | 36 | $36,974 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 567 | $15,760 |
| Rivastigmine | 27 | $7,330 |
| Gabapentin | 205 | $4,800 |
| AmantadineAmantadine Hcl | 68 | $4,336 |
| Primidone | 155 | $3,560 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 125 | $3,235 |
| Entacapone | 32 | $2,703 |
| Rasagiline Mesylate | 23 | $2,629 |
| Ropinirole ErRopinirole Hcl | 24 | $2,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $157 | $847,132123 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $273 | $489,69279 claims |
| Acadia Pharmaceuticals IncNuplazid | $222 | $178,53832 claims |
| Amneal Pharmaceuticals LLCRytary | $328 | $136,01686 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 280 neurology providers in Connecticut.
Other neurology in Vernon
- Joy DemarcaidaVernon$267K
- David RussellNew Haven$31.2M
- Peter McAllisterFairfield$15M
- Erin LongbrakeNorth Haven$5.5M
- David HaflerNew Haven$3.5M
- Stewart TepperStamford$1.3M
- Kathleen MullinStamford$1.1M
- Richard NowakNew Haven$1M
- Srinath KadimiFairfield$908K
- Joachrim BaehringNew Haven$831K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.